Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q14432
UPID:
PDE3A_HUMAN
Alternative names:
Cyclic GMP-inhibited phosphodiesterase A; cGMP-inhibited cAMP phosphodiesterase
Alternative UPACC:
Q14432; O60865; Q13348; Q17RD1
Background:
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A, also known as Cyclic GMP-inhibited phosphodiesterase A, plays a pivotal role in cellular signaling by regulating the levels of cAMP and cGMP, crucial second messengers in various physiological processes. Its unique ability to also target cUMP underscores its versatility in cellular functions. Beyond its enzymatic activity, it engages in an E2/17beta-estradiol-induced pro-apoptotic pathway, particularly relevant in high E2 concentration tissues like the placenta.
Therapeutic significance:
The protein's involvement in Hypertension and brachydactyly syndrome, characterized by severe hypertension and early-onset stroke, highlights its potential as a therapeutic target. Understanding the role of cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A could open doors to novel strategies for managing this syndrome and possibly other related cardiovascular disorders.